Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef ...

It’s the first study to show a PCSK9 inhibitor can reduce major events in high-risk patients who haven’t yet had one.

Gout was associated with increased risks for CV events and all-cause mortality, even after adjusting for long-term CV risk profiles and their changes.

If you're a woman from an ethnic minority group hoping to land a job in Germany's tech sector, you might want to rethink your ...

The head of the U.S. Food and Drug Administration’s drug division, Dr. George F. Tidmarsh, resigned on November 2, 2025, one ...

In this week's work column, an expert advises that low-stimulation work numbs your creative and strategic muscles, and once ...